FDA approves bexagliflozin for adults with type 2 diabetes

The FDA approved bexagliflozin, an oral SGLT2 inhibitor, to improve glycemic control for adults with type 2 diabetes, according to a company press release.
The approval of bexagliflozin (Brenzavvy, TheracosBio) is based on results from 23 clinical trials evaluating the safety and efficacy of bexagliflozin with more than 5,000 adults with type 2 diabetes. These trials demonstrated a significant reduction in HbA1c and fasting blood glucose with bexagliflozin treatment after 24 weeks. This treatment can be utilized as a monotherapy or combined with metformin or as an add-on to standard-of-care

The FDA approved bexagliflozin, an oral SGLT2 inhibitor, to improve glycemic control for adults with type 2 diabetes, according to a company press release.
The approval of bexagliflozin (Brenzavvy, TheracosBio) is based on results from 23 clinical trials evaluating the safety and efficacy of bexagliflozin with more than 5,000 adults with type 2 diabetes. These trials demonstrated a significant reduction in HbA1c and fasting blood glucose with bexagliflozin treatment after 24 weeks. This treatment can be utilized as a monotherapy or combined with metformin or as an add-on to standard-of-care